Synergy between serum amyloid A and secretory phospholipase A\textsubscript{2}

Shobini Jayaraman\textsuperscript{1}\textsuperscript{*}, Marcus Fändrich\textsuperscript{2}, Olga Gursky\textsuperscript{1,3}

\textsuperscript{1}Department of Physiology and Biophysics, Boston University School of Medicine, Boston, United States; \textsuperscript{2}Institute of Protein Biochemistry, Ulm University, Ulm, Germany; \textsuperscript{3}Amyloidosis Treatment and Research Center, Boston University School of Medicine, Boston, United States

Abstract
Serum amyloid A (SAA) is an evolutionally conserved enigmatic biomarker of inflammation. In acute inflammation, SAA plasma levels increase \(\sim\) 1,000 fold, suggesting that this protein family has a vital beneficial role. SAA increases simultaneously with secretory phospholipase A\textsubscript{2} (sPLA\textsubscript{2}), compelling us to determine how SAA influences sPLA\textsubscript{2} hydrolysis of lipoproteins. SAA solubilized phospholipid bilayers to form lipoproteins that provided substrates for sPLA\textsubscript{2}. Moreover, SAA sequestered free fatty acids and lysophospholipids to form stable proteolysis-resistant complexes. Unlike albumin, SAA effectively removed free fatty acids under acidic conditions, which characterize inflammation sites. Therefore, SAA solubilized lipid bilayers to generate substrates for sPLA\textsubscript{2} and removed its bioactive products. Consequently, SAA and sPLA\textsubscript{2} can act synergistically to remove cellular membrane debris from injured sites, which is a prerequisite for tissue healing. We postulate that the removal of lipids and their degradation products constitutes a vital primordial role of SAA in innate immunity; this role remains to be tested in vivo.

DOI: https://doi.org/10.7554/eLife.46630.001

Introduction
The serum amyloid A (SAA) family consists of 12-kDa proteins that have been highly evolutionally conserved at least since the Cambrian period, from sea cucumber to human (Uhlar et al., 1994; Sun et al., 2016). SAA is an enigmatic biomarker of inflammation that is better known as a protein precursor of systemic amyloid A (AA) amyloidosis, a life-threatening complication of chronic inflammation, than for its beneficial action (Westermark et al., 2015; Papa and Lachmann, 2018). Inducible human SAA is produced mainly by the liver under the control of pro-inflammatory cytokines, is secreted into blood, and binds its major plasma carrier, high-density lipoprotein (HDL) (Benditt and Eriksen, 1977). SAA is also secreted locally at inflammation sites and is implicated in cytokine production and immune cell recruitment to these sites (De Buck et al., 2016; Eklund et al., 2012; Ye and Sun, 2015). During the acute-phase response, which is a complex systemic response to severe inflammation, infection or injury (Gabay and Kushner, 1999), human SAA isoforms 1, 2 and 3 are upregulated (Uhlar and Whitehead, 1999), while isoform 4 is constitutively expressed at much lower levels (reviewed in Sun et al., 2016 and in De Buck et al., 2016). Plasma levels of inducible SAA are elevated in infections such as tuberculosis, in autoimmune disorders such as rheumatoid arthritis, lupus, and Crohn’s disease, and in certain cancers (De Buck et al., 2016; Eklund et al., 2012; Ye and Sun, 2015; Sack, 2018). Although chronically elevated SAA is deleterious as a protein precursor of amyloidosis and as a causal risk factor for atherosclerosis (Eklund et al., 2012; Getz et al., 2016; Thompson et al., 2018), the beneficial action of SAA is less clear. In fact, SAA has been reported to be pro- or anti-inflammatory in various studies, and its functions in acute and
chronic inflammation remain enigmatic (reviewed in Eklund et al., 2012, Ye and Sun, 2015, Sack, 2018, and Kisilevsky and Manley, 2012).

Remarkably, in acute inflammation, during infection, after injury or following surgery, plasma levels of SAA increase swiftly more than 1,000-fold, reaching up to 3 mg/ml in 24–48 hr, and then the levels drop (Sun et al., 2016; De Buck et al., 2016; Uhlar and Whitehead, 1999; Sack, 2018). The advantage for survival of this dramatic but transient increase is unclear. However, high sequence conservation in this ancient protein family (Uhlar et al., 1994; Sun et al., 2016) and a major and rapid commitment of liver and local tissues to SAA biosynthesis suggest that SAA is vital for survival.

One potential beneficial role of SAA is its ability to mobilize HDL cholesterol for cell repair. In the acute-phase response, SAA becomes a major HDL protein that can reroute the transport of HDL cholesterol by interacting with several cellular scavenger receptors that bind SAA-modified HDL (reviewed in Kisilevsky and Manley, 2012). However, HDL undergoes additional modifications during the acute-phase response (Jahangiri, 2010; Tall and Yvan-Charvet, 2015), and the role of SAA in the homeostasis of these modified HDLs can be relatively minor (de Beer et al., 2013). Moreover, rerouting HDL cholesterol transport cannot explain rapid and massive secretion of SAA over a period of hours following the onset of acute inflammation in various organisms, including those lacking HDL. Hence, the key primordial function of SAA must be different from HDL homeostasis.

Although most circulating SAA is bound to HDL, like other HDL proteins, SAA is an exchangeable apolipoprotein that can transiently dissociate in a labile ‘free’ form (Wilson et al., 2018). Free SAA can bind a range of other apolar ligands, including cholesterol (Liang et al., 1996), retinol (Derebe et al., 2014), phospholipids, lysophospholipids, and free fatty acids (FFA) (Takase et al., 2014; Jayaraman et al., 2015; Frame and Gursky, 2016; Tanaka et al., 2017; Jayaraman et al., 2017a; Frame et al., 2017; Jayaraman et al., 2018). Our in vitro studies showed that SAA binds various phospholipid vesicles and spontaneously solubilizes them to form HDL-sized particles de novo (Frame et al., 2017; Jayaraman et al., 2018). We proposed that this ability hinges upon the binding of diverse apolar ligands at a large concave apolar face of the SAA molecule (Frame and Gursky, 2016). This face, formed by two amphipathic α-helices, was observed in the atomic-resolution x-ray crystal structures of human SAA1.1 and murine SAA3 (Derebe et al., 2014;
Lu et al., 2014). The shape of this apolar face, whose key features are conserved in the SAA family (Frame and Gursky, 2016), helps to explain the preferential binding of SAA to highly curved apolar surfaces, a property that is essential for HDL binding and lipid sequestration (Frame and Gursky, 2016; Frame et al., 2017). These findings compelled us to propose that SAA’s ability to solubilize phospholipid bilayers and to form lipoprotein nanoparticles de novo reflects the primordial role of this Cambrian protein in the removal of cell membrane debris from injured sites, a function that predates SAA binding to HDL (Frame et al., 2017).

Here, we consider a functional link between SAA and another ancient lipophilic plasma protein, phospholipase A2 (PLA2). PLA2 is a superfamily of diverse enzymes that hydrolyze phospholipids in the sn2 position (Burke and Dennis, 2009). The reaction products, lysophospholipids and FFA, are bioactive lipids that are precursors of signaling molecules in many vital processes (Burke and Dennis, 2009). Secretory PLA2 (sPLA2) is a family of pro-inflammatory enzymes that are involved in the immune response (Boyanovsky and Webb, 2009; Murakami et al., 2016), which is especially relevant to SAA. For example, sPLA2 group-IIa (sPLA2-IIa) is an antimicrobial acute-phase reactant whose concentration in plasma and at inflammation sites can increase several hundred-fold simultaneously with that of SAA (Pruzanski et al., 1993). Notably, sPLA2 is co-expressed with SAA and is induced by the same group of pro-inflammatory cytokines (Vadas et al., 1993). Moreover, SAA stimulates smooth muscle cells to express sPLA2-IIa (Sullivan et al., 2010). Clinical studies have reported a direct link between the plasma levels of SAA and the enhanced activity of sPLA2 during the early stages of inflammation, whereas in vitro studies have shown that SAA enhances the remodeling of sPLA2-induced lipoproteins via an unknown mechanism (Pruzanski et al., 1995; Pruzanski et al., 1998). Furthermore, sPLA2 hydrolyzes highly curved micelle-like surfaces in lipoproteins such as HDL (diameter 8–12 nm), but not intact planar bilayers (Heyrup et al., 2004; Halperin and Mouritsen, 2005), whereas SAA preferentially binds to such highly curved surfaces or forms them de novo by solubilizing lipid bilayers (Jayaraman et al., 2018; Lu et al., 2014). Taken together, these findings compel us to postulate not only a spatiotemporal overlap between SAA and sPLA2 at inflammation sites in vivo, but also their potential synergy in lipid clearance (Jayaraman et al., 2016). This study explores this synergy and its mechanism.

Results

SAA augments the lipolysis of both model and plasma lipoproteins by sPLA2

The murine and human SAA isoform 1.1 (mSAA1.1 and hSAA1.1) proteins used in this study are major isoforms that bind HDL and form amyloid in vivo (Westermark et al., 2015). Recombinant mSAA1.1 (hereafter termed SAA for brevity) was used in most experiments. To determine whether and how SAA influences phospholipid hydrolysis by sPLA2, model and plasma lipoproteins that differed in size and composition were used as substrates for either sPLA2 group-III (sPLA2-III), which preferentially hydrolyses phosphatidylcholine (PC), or sPLA2-IIa, which preferentially hydrolyses phosphatidylethanolamine but also acts on PC (Burke and Dennis, 2009; Boyanovsky and Webb, 2009). Unless otherwise stated, both sPLA2-III and sPLA2-IIa enzymes are collectively termed sPLA2.

We first probed how the lipid surface curvature imposed by SAA influences the sPLA2 reaction. SAA was incubated with multilamellar vesicles (MLV) of a model phospholipid palmitoyl-oleoyl-PC (POPC). The results presented in Figure 1 show that SAA solubilized POPC MLV (diameter circa 200 nm) to form smaller SAA-POPC complexes (~8 nm). The time course of this microsolubilization was monitored by turbidity, and its products were observed by non-denaturing PAGE (Figure 1A,B). Increasing the SAA to POPC molar ratio from 1:100 to 1:10 increased the rate of solubilization (Figure 1A) and resulted in the generation of slightly smaller SAA-POPC particles; for all ratios explored, the particle size was 7.5–8.5 nm (Figure 1B). These small particles, along with POPC MLV, were used as substrates for sPLA2, whose enzymatic activity was assessed by measuring free fatty acid products. In the absence of sPLA2, no significant hydrolysis of SAA-POPC particles was detected, but in the presence of sPLA2, extensive hydrolysis of the SAA-POPC particles was observed (Figure 1C). By contrast, MLV were not hydrolyzed by sPLA2: the levels of FFA were below the detection limit of our assay, and thin-layer chromatography showed only the presence of PC (Figure 1D). Consequently, SAA readily solubilizes model phospholipid bilayers such as POPC MLV...
and converts them into small HDL-size particles that provide excellent substrates for sPLA₂. This ability distinguishes SAA from other major HDL proteins, such as apoA-I and apoA-II, which cannot spontaneously solubilize POPC MLV (Figure 1A).

Next, we tested the effects of SAA on the lipolysis of plasma HDL by sPLA₂. Human HDL that contained various amounts of bound SAA (up to 27% of the total protein mass), termed SAA-HDL, were prepared by incubation of HDL with SAA using 1:1 or 4:1 protein weight ratio of exogenous SAA to endogenous apoA-I as described in the ‘Materials and methods’ (Figure 2—figure supplement 1A–C). The lipoprotein fraction containing only HDL-bound proteins was isolated by size-exclusion chromatography (SEC) from the total incubation mixture (marked SEC Fr and total in Figure 2—figure supplement 1B), and was hydrolyzed by sPLA₂. A progressive increase in activity with an increasing amount of bound SAA was observed (Figure 2A,B). As the particle curvature was similar in these experiments, this increased activity must have stemmed from the presence of bound SAA.

To determine whether unbound (free) SAA also enhanced the enzymatic activity of sPLA₂, we used sPLA₂ to hydrolyze total incubation mixtures that contained HDL-bound and free proteins (Figure 2—figure supplement 1A). For the same amount of SAA, the enhancement of lipolytic activity was comparable in the presence of HDL-bound SAA or a mixture of HDL-bound and free SAA (compare 4:1 SAA-HDL Sec Fr in Figure 2A,B with SAA-HDL total in Figure 2C,D). To directly probe the role of free SAA, we incubated it with normal human LDL that does not bind SAA; the mixture (SAA +LDL, Figure 2—figure supplement 1D) was hydrolyzed with sPLA₂. Increased lipolysis was
observed upon addition of free SAA to LDL (Figure 2C,D). Consequently, free SAA augmented the lipolysis by sPLA$_2$-IIa of various model and plasma lipoproteins.

In summary, the results in Figure 1 and Figure 2—figure supplement 1D show that SAA enhances the hydrolysis by sPLA$_2$-III or sPLA$_2$-IIa of diverse substrates, including SAA-POPC complexes, plasma HDL, and plasma LDL. This enhancement reflects the possibilities that: i) SAA not only binds...
to phospholipid bilayers but also remodels them into smaller highly curved HDL-size particles (~8 nm) that are readily hydrolyzed by sPLA₂ (Figure 1D,E), and ii) SAA augments the action of sPLA₂ in a manner that does not involve SAA binding to the substrate, as evident from the SAA-induced enhancement of LDL lipolysis (Figure 2C,D). As we and others have shown that SAA binds FFA and lysoPC in vitro (Tanaka et al., 2017; Jayaraman et al., 2018), the latter effect could stem from interactions of SAA with the products of sPLA₂. This idea was tested as described below.

**Lipid hydrolysis by sPLA₂ in the presence of SAA generates 7–7.5 nm species**

The ~8 nm SAA-POPC complexes formed upon spontaneous solubilization of MLV using 1:10 to 1:100 protein:l lipid molar ratios were nearly invariant in size (Figure 1C). By contrast, SAA incubated with small unilamellar vesicles (SUV) of POPC formed particles that increased in size as protein:l lipid ratio decreased (Frame et al., 2017). Therefore, in the current study, we used POPC SUV to test the effect of particle size on lipolysis by sPLA₂. To test whether lipoprotein hydrolysis by sPLA₂ involved changes in particle size in the absence and in the presence of SAA, we used non-denaturing PAGE to analyze model and plasma HDL before and after the lipolysis. First, SAA-POPC complexes that varied in size from about 8 nm to 22 nm were prepared by incubating SAA with POPC SUV at protein to lipid molar ratios ranging from 1:1 to 1:100. These incubation mixtures were hydrolyzed by sPLA₂ for 3 hr at 37°C as described in ‘Materials and methods’. Non-denaturing PAGE showed that all parent particles were remodeled by sPLA₂ into species that migrated at 7–7.5 nm (Figure 3—figure supplement 1A).

Next, we performed similar studies using plasma HDLs that were either native or enriched with exogenous SAA (SAA-HDL) as described in ‘Materials and methods’; these HDLs were used as substrates for sPLA₂. Before hydrolysis, both native HDL and SAA-HDL ranged in size from about 8.5 to 12 nm. Hydrolysis of native HDL by sPLA₂ caused little change in the particle size distribution and no significant protein release (Figure 3—figure supplement 1B). By contrast, hydrolysis of SAA-HDL led to lipoprotein remodeling into two major protein-containing species, of 10–12 nm and 7–7.5 nm in size (Figure 3—figure supplement 1B). Together, the results in Figure 3—figure supplement 1 suggest that sPLA₂ hydrolysis of SAA-POPC particles and SAA-HDL, but not of native HDL, leads to a release of protein-containing species that have a hydrodynamic size of 7–7.5 nm.

We tested whether similar species were formed upon direct interaction of SAA with hydrolyzed phospholipids. First, POPC SUV were incubated with sPLA₂ for 3 hr at 37°C as described in ‘Materials and methods’, leading to the hydrolysis of 40–50% of the POPC. Next, the hydrolyzed samples were incubated at 25°C for 6 hr with free SAA using protein to PC molar ratios ranging from 1:1 to 1:100. Non-denaturing PAGE showed that the particle size distribution varied depending upon the initial protein to lipid ratio, yet at all ratios, the major protein-containing species were observed at 7–7.5 nm (Figure 3A, right panel). A strikingly similar migration pattern was observed for the SAA-POPC complexes that were formed using 1:1 to 1:100 protein to PC ratios and then hydrolyzed (Figure 3—figure supplement 1A). Therefore, regardless of the order of the events (binding to SAA and hydrolysis by sPLA₂), SAA formed 7–7.5 nm complexes with the hydrolytic products of POPC, suggesting that these complexes represented stable, kinetically accessible species.

Incubation of free SAA with sPLA₂-treated HDL (Figure 3B) or LDL (Figure 3C) also led to the formation of distinct 7–7.5 nm species. Such species were released from parent lipoproteins only in the presence of both SAA and hydrolyzed phospholipids, and were detected in model systems and in plasma lipoproteins (Figure 3A–C). We reasoned that all of these 7–7.5 nm species could represent stable complexes of SAA with the products of phospholipid hydrolysis, and tested this idea in the following experiments.

**SAA sequesters the FFA and lysoPC produced by sPLA₂ in model and plasma lipoproteins**

To determine the properties of the 7–7.5 nm species formed in the presence of SAA and hydrolyzed phospholipids, these species were isolated by density gradient centrifugation. SAA-POPC particles of 8 nm in size, as well as SAA-containing samples of HDL or LDL — containing a 4:1 protein weight ratio of SAA to either apoA-I (which is the major HDL protein) or apoB (which is the major LDL...
protein) — were hydrolyzed with sPLA\textsubscript{2} as described in Figure 3—figure supplement 1. The 7–7.5 nm particles formed upon hydrolysis were isolated in the density range 1.16–1.20 g/ml. In control experiments, three density fractions were taken after centrifugation of SAA-POPC complexes: before hydrolysis (1.16–1.18 g/ml), hydrolyzed SAA-POPC (1.17–1.20 g/ml), and lipid-free SAA (>1.22 g/ml). Non-denaturing PAGE detected no 7–7.5 nm species at 1.16–1.18 g/ml in the control experiments. By contrast, samples of hydrolyzed SAA-POPC clearly showed 7–7.5 nm species in the 1.17–1.20 g/ml density fraction (Figure 4—figure supplement 1). Similar incubation mixtures of SAA with non-hydrolyzed HDL (SAA+HDL) or LDL (SAA+LDL) are shown for comparison.

Figure 3—figure supplement 1 shows non-denaturing PAGE that monitors the remodeling of SAA-containing model and plasma lipoproteins upon their hydrolysis by sPLA\textsubscript{2}.

The following figure supplement is available for figure 3:

**Figure supplement 1.** Non-denaturing PAG...
Lipid composition in this species was assessed by thin-layer chromatography and enzymatic assays. Both PC and lysoPC were observed in the ~7 nm species isolated from all hydrolyzed lipoproteins, including SAA-POPC, SAA-HDL, and SAA-containing LDL samples (Figure 4E). FFA and phospholipid assays showed 30–45% FFA and 12–22% PC as a weight fraction of total lipids in these ~7 nm species. We conclude that SAA sequesters the FFA and lysoPC that are produced upon the lipolysis of diverse lipoproteins by sPLA₂, and removes these hydrolytic products from the parent particle in the form of ~7 nm protein-lipid complexes. These complexes are heterogeneous and their exact size and biochemical composition vary depending on the parent lipoproteins, yet they all contain SAA and the products of lipolysis.

SAA forms stable complexes with the products of sPLA₂ hydrolysis of model lipoproteins

Previous studies showed that the binding of SAA to POPC and other phospholipids induces \( \alpha \)-helical folding in this intrinsically disordered protein at ambient temperatures, greatly increasing the thermal stability of SAA and protecting it from proteolysis (Takase et al., 2014; Jayaraman et al., 2015; Frame et al., 2017; Lu et al., 2014). To probe whether the SAA-containing complexes that are released upon hydrolysis of these precursors also formed stable structures, these ~7 nm complexes were isolated by density in the 1.17–1.20 g/mL range, and their secondary structure and stability were assessed by circular dichroism (CD) spectroscopy. Far-UV CD spectra at 25°C showed a major conformational change, from a largely unfolded secondary structure in free SAA to ~40% \( \alpha \)-helix in complexes with lipids. Notably, the lipid-bound secondary structure was very similar in the parent SAA-POPC particles and in the ~7 nm products that are released upon lipolysis (Figure 5A).
The structural stability of the ~7 nm products was assessed by measuring the CD signal at 222 nm as a function of temperature to monitor helical unfolding and refolding during heating and cooling from 5°C to 95°C. The heating data for the precursor particles and the ~7 nm product species partially overlapped and showed similar melting temperatures, $T_m = 50 \pm 2^\circ C$ and $48 \pm 2^\circ C$, respectively (Figure 5B), much higher than that of free SAA ($T_m = 17 \pm 2^\circ C$) (Jayaraman et al., 2015; Frame et al., 2017). Therefore, SAA complexes with either intact or hydrolyzed POPC showed comparable thermal stability that was much higher than that of free SAA. Unlike the heating data, the cooling data for the two complexes significantly differed (Figure 5B, gray and black solid lines). For the precursor SAA-POPC particles, the refolding upon cooling was observed at much lower temperatures than the unfolding upon heating. Such a hysteresis is a hallmark of thermodynamically irreversible transitions; in lipoproteins, it reflects irreversible structural remodeling such as fusion (Jayaraman et al., 2015 and references therein). By contrast, free SAA shows a reversible unfolding without a hysteresis (Figure 5B, open circles). Notably, in the ~7 nm SAA complexes formed upon hydrolysis, the heating and cooling transitions were much closer than those in the precursor particles, and the hysteresis was nearly abolished (Figure 5B, gray solid line). This observation is
consistent with the relatively high protein to lipid ratio in the ~7 nm complexes, which is evident from their higher density and smaller size as compared to the precursor particles.

The conformational stability of the ~7 nm complexes was further probed by limited proteolysis as described in ‘Materials and methods’. In contrast to free SAA, which was largely fragmented within 5 min of incubation with trypsin at 22˚C (Figure 5C), the ~7 nm complexes and their SAA-POPC precursor particles resisted proteolysis, and they underwent no major fragmentation even after 12 hr of incubation (Figure 5C). These results agree with the CD data showing more helical structure and increased stability in lipid-bound SAA when compared with free SAA (Figure 5A,B).

Together, the results showed that SAA forms ~7 nm complexes with the hydrolytic products of sPLA₂ (Figure 3—figure supplement 1, Figure 4—figure supplement 1, Figure 5). Although these complexes migrate in the same size range as free SAA on the non-denaturing gel, their structure is distinct from that of either free SAA or the SAA-POPC precursor particles. Unlike free SAA, which shows unfolded secondary structure when examined by CD and is rapidly degraded by trypsin at ambient temperatures, SAA in the ~7 nm complexes is ~40% helical and resists proteolysis (Figure 5A–C), thereby resembling the SAA-POPC precursors. In contrast to precursors, these ~7 nm complexes: i) contain large amounts of FFA and lysoPC (Figure 4); ii) have smaller size (6.5–7.5 nm) and higher density (1.17–1.20 g/mL) indicative of a higher protein to lipid ratio; and iii) undergo a more thermodynamically reversible thermal unfolding (Figure 5B). The latter is consistent with the kinetically accessible character of these product complexes suggested by their similarity, regardless of the order of SAA binding and sPLA₂ hydrolysis (Figure 3A, Figure 3—figure supplement 1A). To our knowledge, such small stable protein-rich proteolysis-resistant complexes comprised of SAA and the products of phospholipid hydrolysis have not been reported previously.

**SAA forms stable complexes with the products of sPLA₂ hydrolysis of plasma lipoproteins**

To ascertain that the high structural stability of the SAA complexes with the products of phospholipid hydrolysis is not limited to model systems, we analyzed the conformation and stability of the ~7 nm complexes isolated from a mixture of SAA and sPLA₂-hydrolyzed plasma lipoproteins. The complexes released from the hydrolyzed SAA-HDL contained both SAA and apoA-I (Figure 4A,B). Owing to difficulties in dissecting the contributions from individual proteins, these complexes were not explored in detail. Instead, we focused on the ~7 nm complexes released from hydrolyzed LDL in the presence of SAA. Such complexes contained SAA as their sole protein (Figure 4C,D), facilitating a direct comparison with a model SAA-POPC system.

Parent LDL was hydrolyzed with sPLA₂ and incubated with SAA, leading to the formation of 7–7.5 nm SAA-only complexes (Figure 3C) that were isolated by density at 1.17–1.20 g/mL. Far-UV CD spectra of these complexes revealed a ~40% a-helical conformation (Figure 5—figure supplement 1A), similar to that seen in the ~7 nm complexes released upon lipolysis of SAA-POPC (Figure 5A). Moreover, similar to these model complexes, thermal unfolding of the LDL-derived SAA-containing complexes was observed with T_m = 45 ± 2˚C and was largely thermodynamically reversible (Figure 5—figure supplement 1B). Finally, limited proteolysis ascertained the high conformational stability of SAA in these complexes, which resisted fragmentation upon incubation with trypsin at 22˚C for up to 24 hr (Figure 5—figure supplement 1C).

We conclude that SAA sequesters the hydrolytic products of sPLA₂ from model and plasma lipoproteins and forms stable ~7 nm complexes with these products. These complexes migrate in the same size range on the non-denaturing gel as free self-associated mSAA1.1. However, unlike free SAA that is structurally labile, the protein in these complexes acquires a stable highly a-helical proteolysis-resistant conformation at ambient temperatures.

**SAA forms stable binary complexes with FFA and with lysoPC**

Hydrolysis of POPC by sPLA₂ generates equimolar amounts of oleic acid (OA) and lysoPC. Upon incubation with OA, SAA was previously shown to form spontaneously binary SAA-OA complexes that migrate at ~7.5 nm; the protein in these complexes was ~40% a-helical at 25˚C and resisted trypsic digestion (Jayaraman et al., 2018). Here, we explored the formation and properties of binary complexes of SAA with lysoPC. The complexes were formed as described in the ‘Materials and methods’ by incubating SAA with lysoPC at 1:10 protein to lipid molar ratio; similar experiments
with POPC were used as a control. Non-denaturing PAGE showed SAA-lysoPC particles of ~8 nm in size, similar to those of SAA-POPC formed at 1:10 molar ratio of protein to lipid (Figure 5—figure supplement 2A). Far-UV CD spectra showed substantial α-helical content in SAA-lysoPC particles, slightly lower than that in SAA-POPC particles (35% versus 40%) (Figure 5—figure supplement 2B). Thermal unfolding of SAA-lysoPC particles was observed with $T_m = 45^\circ C$, slightly lower than 50°C seen in SAA-POPC (Figure 5—figure supplement 2C). Unlike SAA-POPC particles, SAA-lysoPC particles showed little hysteresis during thermal unfolding and refolding. Moreover, similar to other SAA-lipid complexes, SAA-lysoPC complexes resisted tryptic digestion (Figure 5—figure supplement 2D).

Together, our results showed that SAA forms binary complexes with OA and with lysoPC. The protein in these complexes is 35–40% α-helical and resists proteolysis at ambient temperatures; the thermal unfolding is centered at $T_m = 45–48^\circ C$ and is largely thermodynamically reversible. In this regard, these binary complexes of SAA-OA and SAA-lysoPC resemble the quaternary complexes containing SAA, OA, lysoPC and POPC (Figure 5). Clearly, SAA can sequester POPC and its hydrolytic products, either separately or together, to form highly α-helical proteolysis-resistant complexes that are thermodynamically stable at ambient temperatures.

**Relevance to disease and comparison with FFA removal by albumin**

Next, we tested whether SAA can sequester the naturally occurring hydrolytic products from human lipoproteins. Our focus was on the FFA that are elevated in diabetes, inflammation and other diseases. LDL was isolated from the pooled plasma of subjects who were either normolipidemic or had diabetes mellitus, as previously described (Jayaraman et al., 2017b). The content of endogenous FFA in these diabetic LDL was 20% higher than that in normolipidemic LDL (Jayaraman et al., 2017b). SAA was incubated with LDL using 1:1 weight ratio of SAA to apoB. Non-denaturing PAGE showed that the SAA-containing ~7.5 nm complexes were released from diabetic as well as normolipidemic LDL (Figure 6—figure supplement 1A), similar to those released from LDL upon hydrolysis by sPLA$_2$ in the presence of SAA (Figure 3C, Figure 2—figure supplement 1D). This result suggests that SAA sequesters exogenous and endogenous FAA from lipoproteins to form similar-size complexes.

Under normal in vivo conditions, FFA and lysoPC are transported in plasma mainly by serum albumin. In acute inflammation, plasma levels of albumin and its ability to sequester FFA and lysoPC decrease, while the levels of sPLA$_2$ and SAA increase (Gabay and Kushner, 1999; Pruzanski and Vadas, 1991; Fichtlscherer et al., 2004). Is it possible for SAA to assume albumin’s function under these conditions? To explore this, we compared the ability of SAA and albumin to remove endogenous FFA from plasma LDL. LDL from diabetic and healthy normolipidemic subjects (0.2 mg/ml apoB) was incubated at pH 7.5, 37°C, for 6 hr with 0.2 mg/ml SAA (2% w/v). A similar LDL incubation was carried out with 2% w/v human serum albumin. As a control, LDL was incubated under similar conditions without any added proteins. LDL was isolated by SEC and the FFA content was determined. The results showed that both albumin and SAA removed a large portion of endogenous FFA from diabetic as well as normolipidemic LDL, and that albumin was slightly more efficient than SAA at pH 7.5 (Figure 6—figure supplement 1B). This finding suggests that SAA can potentially contribute to FFA removal at plasma pH, albeit less efficiently than albumin.

Next, we tested whether SAA can remove FFA at acidic pH, which severely impairs albumin’s function (Lähdesmäki et al., 2009). Previously, we showed that the SAA structure, stability and ability to remodel POPC MLV remain invariant at pH 7.5–5.5 but are altered at near-lysosomal pH (Jayaraman et al., 2017a). Here, we explored how pH influences the ability of SAA to remove FFA from human lipoproteins. Single-donor LDLs were hydrolyzed with sPLA$_2$ and incubated either with SAA, with albumin, or alone (control) for 6 hr at pH ranging from 4.5 to 7.5. Thereafter, LDL was isolated by density gradient centrifugation and the FFA content was measured. As expected, albumin was less efficient at removing FFA at acidic pH than at pH 7.5; this was evident from the higher residual content of FFA detected in LDL at pH 4.5–6.5 versus that at pH 7.5 (Figure 6, LDL + albumin). By contrast, SAA’s ability to remove FFA remained invariant at pH 4.5–7.5 (Figure 6, LDL + SAA). Importantly, at acidic pH, when the activity of albumin but not SAA was impaired, SAA removed more FFA than albumin per gram of protein (Figure 6, LDL + SAA and LDL + albumin compared). This finding strongly supports the role of SAA in FFA removal in vivo and suggests that this role becomes particularly important at the acidic pH that are typical of inflammation sites. This role is
expected to be important in inflammation and in other conditions in which SAA level increases while albumin level and activity declines.

**Human and murine SAA1.1 sequester the products of phospholipid hydrolysis**

To ascertain the relevance of these findings to humans, selected experiments were performed using hSAA1.1 and either model or plasma lipoproteins that were hydrolyzed by sPLA$_2$. Human and
murine SAA1.1 show striking sequence, structural and functional similarities (Rennegarbe et al., 2017). Compared to mSAA1.1, hSAA1.1 is less water-soluble in the lipid-free state and forms larger ~9 nm oligomers on the non-denaturing PAGE (hSAA, Figure 6—figure supplement 2A) relative to the ~7.5 nm oligomers formed by free mSAA1.1 (Figure 1B, Figure 4—figure supplement 1A, Figure 6—figure supplement 1A). Importantly, non-denaturing PAGE showed that, similar to mSAA1.1, hSAA1.1 spontaneously formed 8.5–9 nm particles upon incubation with POPC SUV at a 1:10 protein to lipid molar ratio (hSAA-POPC, Figure 6—figure supplement 2A). Upon hydrolysis with sPLA₂-IIa or sPLA₂-III, these 8.5–9 nm particles were remodeled into ~7.5 nm complexes (sPLA₂-hydrolyzed, Figure 6—figure supplement 2A), similar to those formed by mSAA1.1 (sPLA₂-hydrolyzed 1:10, Figure 3—figure supplement 1A).

Further, when hSAA1.1 was incubated with LDL that have been hydrolyzed with sPLA₂, it also formed complexes that migrated at ~7.5 nm (hSAA + LDL, Figure 6—figure supplement 2B). Complexes of similar size were formed by mSAA1.1 upon sequestration of lipolytic products from LDL (SAA + hydLDL, Figure 4—figure supplement 1C). These comparisons suggest that, similar to mSAA1.1, hSAA1.1 sequesters the products of phospholipid hydrolysis from model and plasma lipoproteins to form ~7.5 nm particles. Finally, FFA analysis of LDL from the plasma of normolipidemic and diabetic patients that have been incubated with SAA and then re-isolated by density showed that, similar to mSAA1, hSAA1.1 sequestered a major fraction of FFA from these LDL (Figure 6—figure supplement 2C). Together, these results suggest that, similar to mSAA1.1, hSAA1.1 can sequester phospholipids and their lipolytic products into HDL-size particles.

Discussion
This in vitro study demonstrates that two ancient acute-phase plasma proteins, sPLA₂ and SAA, act in synergy to break down and remove phospholipids. The increased lipolytic activity of sPLA₂ on HDL upon the addition of SAA was previously reported but the mechanism was unknown (Pruzanski et al., 1995). The current study shows that SAA enhances the lipolysis by sPLA₂ of diverse lipid assemblies, including model phospholipid vesicles as well as human HDL and LDL (Figures 1 and 2), and that the mechanism involves direct SAA-mediated enhancement of sPLA₂ activity. We show that SAA augments the sPLA₂ reaction both by generating highly curved substrates for sPLA₂ (Figure 1) and by removing its reaction products, FFA and lysophospholipids (Figure 4). The latter may well be particularly important because product removal determines the reaction rate of many lipases including sPLA₂ (Carman et al., 1995). Together, these findings expand the previously postulated housekeeping roles of SAA in solubilizing and clearing cellular membrane phospholipids from injured sites (Frame et al., 2017) and in providing an anti-oxidant for lipoproteins by sequestering lipid peroxides (Jayaraman et al., 2016). Our results suggest that sequestration of membrane lipids and their degradation products by SAA and the safe removal of these bioactive products from the injured sites, which is a prerequisite for tissue healing, represents a vital role of this Cambrian protein.

Unlike SAA, several other acute-phase reactants either have no effect on sPLA₂ activity or inhibit it, which perhaps helps to control the resolution of inflammation (Pruzanski et al., 1996). To our knowledge, SAA is the only acute-phase protein that enhances the activity of sPLA₂. The in vivo synergy between SAA and sPLA₂ is probably facilitated by the simultaneous secretion of these proteins systemically as well as locally at the inflammation sites. Furthermore, both proteins show preference for highly curved lipid surfaces that can be generated by SAA (Figure 1; Frame et al., 2017; Jayaraman et al., 2018) and are required for the activation of sPLA₂. This is expected to lead to spatiotemporal overlap between SAA and sPLA₂, facilitating their synergy at the inflammation sites.

We propose that the ability of SAA to sequester diverse phospholipids and their degradation products, which was demonstrated in the current and previous studies by us and others (Takase et al., 2014; Tanaka et al., 2017; Frame et al., 2017; Jayaraman et al., 2018; Jayaraman et al., 2016), underlies several beneficial effects. First, SAA can spontaneously solubilize diverse phospholipid bilayers in vitro (Figure 1A,B; Jayaraman et al., 2018), and perhaps in vivo, which is particularly relevant with respect to dead cells whose normal lipid efflux to HDL via ATP-driven transporters is impaired (Frame et al., 2017). By contrast, lipid sequestration by SAA is energy-independent (Figure 1A). The resulting stable nanoparticles are hydrolyzed by sPLA₂ (Figure 1C; also see Jayaraman et al., 2018) and/or perhaps are internalized by
macrophages through scavenger receptors such as CD36 or SR-BI that bind SAA (Eklund et al., 2012; Frame et al., 2017 and references therein). Second, SAA solubilizes lysoPC and FFA and sequesters them into small particles (Figure 3) that are stable, substantially α-helical, and resist proteolysis at 37°C (Figure 5). This sequestration augments the sPLA₂ reaction; it is also expected to facilitate the safe removal of toxic lipolytic products by SAA while protecting free SAA from unfolding and rapid degradation. Third, consistent with these findings, previous studies showed that SAA protects human lipoproteins from oxidation in vitro (Jayaraman et al., 2016) and in vivo (Sato et al., 2016). This anti-oxidant effect is mediated mainly by free (rather than HDL-bound) SAA that probably sequesters lipid hydroperoxides and safely removes them from lipoproteins (Jayaraman et al., 2016), in a manner similar to the SAA-mediated removal of FFA and lysoPC described in the current study. Together, these findings suggest that during inflammation, when oxidative stress and lipolysis are increased, SAA augments the action of serum albumin by removing FFA, lysoPC, lipid peroxides and, potentially, other products of lipid degradation. We speculate that free SAA, like albumin, serves as a lipid scavenger that sequesters diverse lipophilic molecules. Unlike albumin, SAA forms oligomers to sequester lipids. Although the structure of these oligomers is unknown, lipids are expected to bind in a hydrophobic cavity formed by concave apolar faces of amphipathic helices from several protein molecules (Frame and Gursky, 2016; Frame et al., 2017). The high stability of SAA complexes with lipids and their hydrolytic products contrasts with the marginal in vitro stability of lipid-free SAA oligomers at pH above pH 5 (Jayaraman et al., 2017a and references therein). We speculate that these marginally stable protein oligomers are primed for interaction with lipids to form stable complexes like those reported in the current study.

Normally, serum albumin removes a major fraction of sPLA₂ products. However, albumin is a negative acute-phase reactant whose plasma levels drop sharply in inflammation, with a concomitant steep increase in positive reactants, such as SAA and sPLA₂ (Gabay and Kushner, 1999). In addition, albumin’s ability to remove FFA is compromised upon the protein’s post-translational modifications in inflammation (Lee and Wu, 2015). Moreover, albumin’s capacity to remove FFA decreases under acidic conditions (Figure 6), which are characteristic of inflammation sites (Lähdesmäki et al., 2009). All together, these effects are expected to cause an imbalance between the massive generation of FFA and lysoPC at inflammation sites and the impaired removal of these molecules by albumin. Our finding that, per gram of protein, SAA is more efficient than albumin in removing FFA from plasma lipoproteins at acidic pH (Figure 6) suggests that SAA acts locally at the sites of inflammation to compensate for the impaired albumin activity, and helps to remove excess lipids and the products of their hydrolysis and oxidation. We propose that the ability to sequester diverse lipids and their degradation products, which is rooted in the unique structure of SAA with its concave hydrophobic surface that has been highly conserved throughout evolution (Frame and Gursky, 2016), constitutes a previously unknown vital role of SAA in the immune response. This role remains to be tested in future cell-based and in vivo studies.

Materials and methods

Proteins and lipids

Recombinant murine SAA isoform 1.1 (103 amino acids, 11.6 kDa) was used throughout this study; it is termed mSAA1.1, or SAA for brevity. SAA was expressed in Escherichia coli and purified to 95% purity as described previously (Kollmer et al., 2016). In selected experiments, we used recombinant human SAA isoform 1.1 (hSAA1.1, 104 amino acids, cat. # SRP4324) from Sigma. Essentially fatty acid-free human serum albumin (cat. # A1887) was from Sigma. Lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC; C16:0, C18:1) and lysoPC (16:0) were 97% + pure from Avanti Polar Lipids. Trypsin from bovine pancreas (cat. # T1426), group-III sPLA₂ (sPLA₂-III, cat. # P9279), lipoprotein lipase (cat. # L2254), sphingomyelinase from Bacillus cereus (cat. # S9396), and sodium oleate (cat # O7501) were from Sigma. Human recombinant group-IIa sPLA₂ (sPLA₂-IIa, cat. # RD172054100) was from Biovendor. Enzymochrom free fatty acid assay kit (cat. # EFFA-100) and Enzymochrom phospholipid assay kit (cat. # EPLP-100) were from Fisher Scientific. Ultrapure sodium phosphate buffer at pH 7.5 (BB-148) was from Boston Bioproducts. All other chemicals were of the highest purity analytical grade.
SAA stock solutions were prepared daily by dissolving lyophilized protein at 1 mg/ml in water and dialyzing it overnight against the standard buffer (50 mM sodium phosphate, 150 mM NaCl, pH 7.5). SAA stock solutions were centrifuged at 10,000 g for 10 min prior to each experiment to remove protein aggregates. Recombinant hSAA1 was reconstituted according to the manufacturer’s recommendations and was immediately diluted in standard buffer, followed by overnight dialysis in standard buffer prior to use. Protein concentrations were determined by a bicinchoninic acid assay.

**Human plasma lipoproteins**

Unless otherwise stated, single-donor human lipoproteins from three healthy volunteers were used throughout this study. Plasma from anonymous healthy donors was obtained commercially from the local blood bank according to the rules of the institutional review board. Single-donor lipoproteins were isolated following published protocols (Schumaker and Puppione, 1986) from fresh EDTA-treated plasma by KBr density gradient ultracentrifugation in the density range 0.94–1.006 g/mL for VLDL, 1.019–1.063 g/mL for LDL, and 1.063–1.21 g/mL for HDL. Lipoproteins from each class migrated as a single band on the agarose and non-denaturing gels. Lipoprotein stock solutions were prepared by extensive dialysis against 50 mM sodium phosphate buffer, 150 mM NaCl, 0.25 mM EDTA, 0.02% NaN₃, pH 7.5, degassed, and stored in the dark at 4˚C. Each stock solution was used within two weeks during which no protein degradation was detected by SDS PAGE and no changes in the lipoprotein electrophoretic mobility were observed by agarose PAGE.

To obtain HDL enriched with exogenous SAA (termed SAA-HDL), single-donor HDL were isolated from healthy subjects and were incubated with SAA at 37˚C for 6 hr in standard buffer. The molar ratio of SAA to apoA-I varied from 0:1 (SAA-free control) to 4:1. Free (uncomplexed) proteins, which contained excess SAA as well as apoA-I that was displaced from HDL by SAA, were removed by size exclusion chromatography (SEC) as previously described (Jayaraman et al., 2015). The total incubation mixture before purification is termed SAA-HDL(total) and the SEC-purified lipoprotein fraction is termed SEC Fr (Figure 2—figure supplement 1A,B). As a control, HDL were incubated without SAA under otherwise identical conditions; no changes in the particle size, composition or stability were detected upon such incubation. Total protein concentration was determined by bicinchoninic acid assay, and individual apolipoprotein content was determined as a weight fraction of the total protein by quantifying SDS gel bands using Image J software, as described previously (Jayaraman et al., 2015). Intact non-modified HDL contained 75% apoA-I and 25% apoA-II; SAA-HDL (1:1 mol:mol SAA:apoA-I, SEC fr) contained 65% apoA-I, 23% apoA-II and 12% SAA; and SAA-HDL (4:1, SEC fr) contained 56% apoA-I, 17% apoA-II and 27% SAA (Figure 2—figure supplement 1C).

To explore the effects of SAA on LDL, SAA (1 mg/ml) was incubated with single-donor normolipidemic plasma LDL (1 mg/ml apoB) in standard buffer at 37˚C for 3 hr. The mixture was analyzed by SEC and non-denaturing PAGE to ascertain that SAA did not bind LDL (Figure 2—figure supplement 1D).

To compare human LDLs that vary in endogenous FFA levels, plasma was pooled from 25 patients diagnosed with type-2 diabetes mellitus and from 25 healthy normolipidemic subjects, as previously described (Jayaraman et al., 2017b). Plasma was obtained at the Lipid Laboratory of Hospital de Saint Pau and LDL were isolated by density gradient centrifugation in the laboratory of Dr. Jose Luis Sanchez-Quesada at the Hospital de Saint Pau (Barcelona, Spain); these studies were done with the written informed consent of the patients and upon approval by the institutional ethics committee, as previously described (Jayaraman et al., 2017b). The FFA content, which was quantified by an enzymatic assay described below, was 20% higher in diabetic than in normolipidemic LDL.

**Reconstituted lipoproteins**

Lipoproteins were reconstituted using a thin film evaporation method. POPC was dissolved in chloroform:methanol (2:1 v/v), the organic solvent was evaporated under nitrogen stream, and the samples were dried under vacuum overnight at 4˚C. MLVs were prepared by dispersing the lipid film in standard buffer followed by vortexing. SUVs (diameter ~22 nm) were prepared by sonication of MLVs and were used within one day.

SAA-containing lipoproteins of controlled size were prepared by incubating SAA with POPC SUV at 25˚C for 3 hr using an SAA to POPC molar ratio of either 1:100 (to prepare SAA-containing SUVs of ~22 nm in size) or 1:10 (to prepare SAA-POPC complexes of 8 nm in size). Excess lipid was...
removed by centrifugation and excess protein was removed by SEC. The protein to lipid weight ratio in the final preparations was 1:42 (for 1:100 mol:mol initial ratio) or 1:28 (for 1:10 mol:mol initial ratio).

SAA complexes with oleic acid were reconstituted as described by Jayaraman et al. (2018). To reconstitute SAA complexes with lysoPC, SAA was incubated with freshly prepared lysoPC at 37°C for 1 hr at protein:lipid molar ratios varying from 1:1 to 1:100. This range encompassed lysoPC concentrations below and above its critical micelle concentration (4–8.3 mM).

**Lipid clearance**
MLV clearance by SAA at room temperature was monitored by turbidity at 325 nm using a Varian Cary-300 UV-vis spectrophotometer. SAA (20 μg/ml) was rapidly mixed with MLV suspension in standard buffer (40 μg/ml lipid), and the time course of turbidity changes was recorded as micron-size MLVs were converted into smaller lipoprotein nanoparticles. MLVs alone were used as controls.

**Enzymatic lipolysis**
SAA-POPC complexes (10 μM lipid), as well as human plasma HDL and LDL (0.5–1.0 mg/ml total protein), were used as substrates for sPLA₂. First, the lipoproteins were dialyzed against 10 mM Tris buffer saline at pH 7.5. Phospholipid lipolysis was performed using 50 nm human recombinant sPLA₂-lla or bee-venom sPLA₂-III in TBS at pH 7.4 in the presence or absence of 2% w/v of fatty-acid-free bovine serum albumin and 2 mM CaCl₂. After a 3 hr incubation at 37°C, the reaction was terminated by adding EDTA (final concentration 20 mM). To assess the spontaneous lipolysis of phospholipids, control experiments were carried out under identical conditions without sPLA₂. Hydrolysis of POPC SUV by sPLA₂ without SAA was also quantified as a control. The extent of hydrolysis was assessed by measuring the FFA products using an enzymatic assay kit (Wako Chemicals).

**Lipid assays**
FFA and total phospholipids were quantified using kits from Bioassay Systems (Enzycrhom™ free fatty assay kit EFFA-100, and Enzychrom™ phospholipid assay kit EPLP-100), according to the manufacturer’s instructions.

Lipoprotein lipids were assayed by thin layer chromatography using samples containing 0.5 mg/ml protein. The lipids were extracted following published protocols (Folch et al., 1957), the organic solvent was dried, and the lipids were spotted on the plate (glass backed, plain silica gel). The tank was first saturated with a chloroform:methanol:water (32.5:12.5:2 v/v/v) solvent system. The plate was developed for 1 hr. The spots were identified by charring with sulfuric acid spray.

**Circular dichroism spectroscopy**
CD data were recorded using an AVIV 62DS spectropolarimeter to monitor protein secondary structure and thermal stability. Far-UV CD spectra were recorded at 190–250 nm from solutions containing 0.1 mg/ml SAA in standard buffer. Melting data were recorded at 222 nm to monitor changes in the α-helical structure during sample heating and cooling at a constant rate of either 70 °C/h or 10 °C/h. The data at these scan rates closely overlapped, consistent with previous studies (Jayaraman et al., 2015). Buffer baselines were subtracted from the data; the results were normalized to the protein concentration and reported as molar residue ellipticity, [θ]222, as previously described (Mao and Wallace, 1984).

**Gel electrophoresis and size-exclusion chromatography**
For non-denaturing PAGE, Novex 4–20% Tris-glycine gels (Invitrogen) were loaded with 6 μg protein per lane and run to termination at 1500 V/h under non-denaturing conditions in Tris-glycine buffer. For SDS PAGE, Novex 16% or 18% Tris-glycine gels were loaded with 5 μg protein per lane and run at 200 V for 1 hr under denaturing conditions in SDS-Tris-glycine buffer. The gels were stained with Denville Blue protein stain (Denville Scientific).

SEC was performed with a Superose 6 10/300 GL column controlled by an AKTA UPC 10 FPLC system (GE Healthcare). Elution by 10 mM PBS at pH 7.5 was carried out at a flow rate of 0.5 ml/min.
Protein cross-linking
SAA oligomerization in SAA-POPC complexes before and after their hydrolysis with sPLA₂ was assessed using glutaraldehyde, which can cross-link free NH₂ groups that are separated by up to 12 Å. SAA-POPC (0.5 mg/ml protein) was incubated for 30 min at 24°C with glutaraldehyde (0.01–0.08%), the reaction was quenched by adding 100 mM Tris, and the samples were analyzed by SDS PAGE. The results were obtained using standard buffer (50 mM sodium phosphate buffer, 150 mM NaCl, pH 7.5), which yielded less non-specific aggregation. The exact cross-linking pattern varied depending on the salt concentration, and more non-specific higher order oligomers were observed in a low-salt buffer.

Limited proteolysis and mass spectrometry
SAA, either in lipid-free form or in complexes with lipids, was incubated with trypsin at 1:1500 mg:mg enzyme:substrate ratio in standard buffer at room temperature. Tryptic digestion was quenched using 2 mM of a serine protease inhibitor, phenylmethylsulfonyl fluoride. The reaction was quenched after 5 min for lipid-free SAA, which was rapidly digested, and after 1 hr for lipid-bound SAA, which was digested much more slowly. The reaction products were analyzed by SDS PAGE and matrix-assisted laser desorption ionization – time of flight mass spectrometry.

For mass spectrometry, the spectra were recorded on a Reflex-IV spectrometer (Bruker Daltonics, Billerica, MA) equipped with a 337 nm nitrogen laser. The instrument was operated in the positive-ion reflection mode at 20 kV accelerating voltage with time-lag focusing enabled. Calibration was performed in linear mode using a standard calibration mixture containing the oxidized B-chain of bovine insulin, equine cytochrome C, equine apomyoglobin, and bovine serum albumin. The matrix, cyano-4-hydroxycinnamic acid (alpha cyano, Mw = 189 g/mol), was prepared as a saturated solution in 70% acetonitrile and 0.1% trifluoroacetic acid in water. Mass spectrometry results were reported as an average of three independent experiments.

Removal of free fatty acids
To compare the ability of SAA and albumin to remove FFA from LDL in a broad range of physiologically relevant pH, samples of single-donor human LDL containing 1 mg/ml apoB were hydrolyzed using 50 nM sPLA₂-III at 37°C for 3 hr at pH 7.5, 6.5, 5.5 or 4.5. The hydrolysis was performed either sPLA₂-III alone, sPLA₂-III with 2% (w/v) FFA-free human serum albumin, or sPLA₂-III with 2% (w/v) SAA. After incubation, LDL were re-isolated by density gradient centrifugation, and their FFA content was quantified by an enzymatic assay. The FFA content in intact LDL from the same batch was also quantified and the results are shown in Figure 6.

To compare the ability of human and murine SAA1.1 to remove endogenous FFA from LDL, pooled plasma LDL from healthy normolipidemic subjects and from diabetic patients were used. LDL were incubated at 37°C for 3 hr at pH 7.5 with either hSAA1.1 or mSAA1.1 using a 1:1 SAA:apoB weight ratio. Thereafter, LDL were re-isolated by density centrifugation and their FFA content was measured. The FFA content of intact LDL from the same batch was also measured (Figure 6—figure supplement 2C).

Reproducibility
To ensure reproducibility, all experiments in this study were performed three or more times, unless otherwise stated. The enzymatic assays were performed in technical triplicates of biological duplicates and are reported as an average of a technical triplicate with the corresponding standard errors of means. Statistical analysis was performed using the ANOVA t-test.

Acknowledgements
We thank Dr. R Andrew Zoeller (Boston University School of Medicine, Boston USA) for help with thin layer chromatography, and Dr. Jose Luis Sanchez-Quesada (Hospital de Saint Pau, Barcelona, Spain) for providing pooled LDL from diabetic and normolipidemic subjects. We are indebted to Dr. Barbara M Schreiber (Boston University School of Medicine, Boston USA) for useful comments on the manuscript prior to submission. This study was supported by the National Institutes of Health.
grant GM067260, by the Stewart Amyloidosis Endowment Fund, and by Deutsche Forschungsgemeinschaft grant FA456/15-1.

Additional information

**Funding**

| Funder                           | Grant reference number | Author                  |
|----------------------------------|------------------------|-------------------------|
| National Institutes of Health    | GM067260               | Shobini Jayaraman Olga Gursky |
| Deutsche Forschungsgemeinschaft  | FA456/15-1             | Marcus Fändrich         |
| Stewart Amyloidosis Endowment Fund |                       | Olga Gursky             |

The funders provide resource to study design, data collection and submit the work for publication.

**Author contributions**

Shobini Jayaraman, Conceptualization, Software, Formal analysis, Validation, Visualization, Methodology, Writing—original draft, Project administration, Writing—review and editing; Marcus Fändrich, Resources, Funding acquisition; Olga Gursky, Resources, Formal analysis, Supervision, Funding acquisition, Investigation, Writing—original draft, Project administration, Writing—review and editing.

**Author ORCIDs**

Shobini Jayaraman [https://orcid.org/0000-0003-1616-5347](https://orcid.org/0000-0003-1616-5347)

Olga Gursky [https://orcid.org/0000-0002-8598-4824](https://orcid.org/0000-0002-8598-4824)

**Decision letter and Author response**

Decision letter [https://doi.org/10.7554/eLife.46630.023](https://doi.org/10.7554/eLife.46630.023)

Author response [https://doi.org/10.7554/eLife.46630.024](https://doi.org/10.7554/eLife.46630.024)

**Additional files**

**Supplementary files**

• Transparent reporting form

DOI: [https://doi.org/10.7554/eLife.46630.021](https://doi.org/10.7554/eLife.46630.021)

**Data availability**

All data generated or analysed during this study are included in the manuscript and supporting files.

**References**

Benditt EP, Eriksen N. 1977. Amyloid protein SAA is associated with high density lipoprotein from human serum. *PNAS* **74**:4025–4028. DOI: [https://doi.org/10.1073/pnas.74.9.4025](https://doi.org/10.1073/pnas.74.9.4025), PMID: 198813

Boyanovsky BB, Webb NR. 2009. Biology of Secretory Phospholipase A2. *Cardiovascular Drugs and Therapy* **23**:61–72. DOI: [https://doi.org/10.1007/s10557-008-6134-7](https://doi.org/10.1007/s10557-008-6134-7)

Burke JE, Dennis EA. 2009. Phospholipase A2 structure/function, mechanism, and signaling. *Journal of Lipid Research* **50**:S237–S242. DOI: [https://doi.org/10.1194/jlr.R800033-JLR200](https://doi.org/10.1194/jlr.R800033-JLR200), PMID: 19011112

Carman GM, Deems RA, Dennis EA. 1995. Lipid signaling enzymes and surface dilution kinetics. *Journal of Biological Chemistry* **270**:18711–18714. DOI: [https://doi.org/10.1074/jbc.270.32.18711](https://doi.org/10.1074/jbc.270.32.18711), PMID: 7642515

de Beer MC, Wróblewski JM, Noffsinger VP, Ji A, Meyer JM, van der Westhuyzen DR, de Beer FC, Webb NR. 2013. The impairment of Macrophage-to-Feces reverse cholesterol transport during inflammation does not depend on serum amyloid A. *Journal of Lipids* **2013**:1–11. DOI: [https://doi.org/10.1155/2013/283486](https://doi.org/10.1155/2013/283486)

De Buck M, Gouwy M, Wang JM, Van Snick J, Opdenakker G, Struyf S, Van Damme J. 2016. Structure and expression of different serum amyloid A (SAA) Variants and their Concentration-Dependent functions during
host insults. *Current Medicinal Chemistry* **23**:1725–1755. DOI: https://doi.org/10.2174/092986732366160418114600, PMID: 27087246

Derebe MG, Zlatkov CM, Gattu S, Ruhn KA, Vaishnava S, Diehl GE, MacMillan JB, Williams NS, Hooper LV. 2014. Serum amyloid A is a retinol binding protein that transports retinol during bacterial infection. *eLife* **3**:e03206. DOI: https://doi.org/10.7554/eLife.03206, PMID: 25073702

Eklund KK, Niemi K, Kovanes PT. 2012. Immune functions of serum amyloid A. *Critical Reviews in Immunology* **32**:335–348. DOI: https://doi.org/10.1615/CritRevImmunol.v32.i4.40, PMID: 23237509

Fichtlscherer S, Kaszkin M, Breuer S, Dommeler S, Zeiher AM. 2004. Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease. *Clinical Science* **106**:511–517. DOI: https://doi.org/10.1042/CS20030399, PMID: 14686876

Folch J, Lees M, Sloane Stanley GH. 1957. A simple method for the isolation and purification of total lipides from animal tissues. *The Journal of Biological Chemistry* **226**:497–509. PMID: 13828781

Frame NM, Jayaraman S, Gantz DL, Gursky O. 2017. Serum amyloid A self-assembles with phospholipids to form stable protein-rich nanoparticles with a distinct structure: A hypothetical function of SAA as a "molecular mop" in immune response. *Journal of Structural Biology* **200**:293–302. DOI: https://doi.org/10.1016/j.jsb.2017.06.007, PMID: 28645735

Frame NM, Gursky O. 2016. Structure of serum amyloid A suggests a mechanism for selective lipoprotein binding and functions: SAA as a hub in macromolecular interaction networks. *FEBS Letters* **590**:866–879. DOI: https://doi.org/10.1002/1873-3468.12116

Gabay C, Kushner I. 1999. Acute-phase proteins and other systemic responses to inflammation. *New England Journal of Medicine* **340**:448–454. DOI: https://doi.org/10.1056/NEJM199902113400607, PMID: 9971870

Getz GS, Krishack PA, Reardon CA. 2016. Serum amyloid A and atherosclerosis. *Current Opinion in Lipidology* **27**:531–535. DOI: https://doi.org/10.1097/MOL.0000000000000331, PMID: 27579547

Halperin A, Mouritsen OG. 2005. Role of lipid protrusions in the function of interfacial enzymes. *European Biophysics Journal* **34**:967–971. DOI: https://doi.org/10.1007/s00249-005-0466-z, PMID: 15883844

Heyrup P, Callisen TH, Jensen Morten Ø., Halperin A, Mouritsen OG. 2004. Lipid protrusions, membrane softness, and enzymatic activity. *Phys. Chem. Chem. Phys.* **6**:1608–1615. DOI: https://doi.org/10.1039/B314146B

Jahangiri A. 2010. High-density lipoprotein and the acute phase response. *Current Opinion in Endocrinology, Diabetes and Vascular Disease** **17**:156–160. DOI: https://doi.org/10.1097/MED.0b013e32833727b6, PMID: 20177380

Jayaraman S, Haupt C, Gursky O. 2015. Thermal transitions in serum amyloid A in solution and on the lipid: implications for structure and stability of acute-phase HDL. *Journal of Lipid Research* **56**:1531–1542. DOI: https://doi.org/10.1194/jlr.M059162, PMID: 26022803

Jayaraman S, Haupt C, Gursky O. 2016. Paradoxical effects of SAA on lipoprotein oxidation suggest a new antioxidant function for SAA. *Journal of Lipid Research* **57**:2138–2149. DOI: https://doi.org/10.1194/jlr.M071191, PMID: 27744369

Jayaraman S, Gantz DL, Haupt C, Gursky O. 2017a. Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis. *PNAS* **114**:E6507–E6515. DOI: https://doi.org/10.1073/pnas.1707120114, PMID: 28743750

Jayaraman S, Sánchez-Quesada JL, Gursky O. 2017b. Triglyceride increase in the core of high-density lipoproteins augments apolipoprotein dissociation from the surface: Potential implications for treatment of apolipoprotein deposition diseases. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* **1863**:200–210. DOI: https://doi.org/10.1016/j.bbadis.2016.10.010, PMID: 27768903

Jayaraman S, Gantz DL, Haupt C, Fändrich M, Gursky O. 2018. Serum amyloid A sequesters diverse phospholipids and their hydrolytic products, hampering fibril formation and proteolysis in a lipid-dependent manner. *Chemical Communications* **54**:3532–3535. DOI: https://doi.org/10.1039/C8CC01424H

Kisilevsky R, Manley PN. 2012. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. *Amyloid* **19**:5–14. DOI: https://doi.org/10.3109/13506129.2011.654294, PMID: 22320226

Kollmer A, Meinhardt K, Haupt C, Liberta F, Wulf M, Linder J, Handl L, Heinrich L, Loos C, Schmidt M, Syrovets T, Simmet T, Westermark P, Westermark GT, Horn U, Schmidt V, Walther P, Fändrich M. 2016. Electron tomography reveals the fibril structure and lipid interactions in amyloid deposits. *PNAS* **113**:5604–5609. DOI: https://doi.org/10.1073/pnas.1523496113, PMID: 27140069

Lähdesmäki K, Pilhari R, Soinnen P, Hurt-Camejo E, Ala-Korpela M, Oärni K, Kovanen PT. 2009. Phospholipase A(2)-modified LDL particles retain the generated hydrolytic products and are more atherogenic at acidic pH. *Atherosclerosis* **207**:352–359. DOI: https://doi.org/10.1016/j.atherosclerosis.2009.04.031, PMID: 19473659

Lee P, Wu X. 2015. Review: modifications of human serum albumin and their binding effect. *Current Pharmaceutical Design* **21**:1862–1865. DOI: https://doi.org/10.2174/1381612821666150302115025, PMID: 25732553

Liàng JS, Schreiber BM, Salmona M, Phillip G, Gonnerman WA, de Beer FC, Sipe JD. 1996. Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells. *Journal of Lipid Research* **37**:2109–2116. PMID: 8906588

Lu J, Yu Y, Zhu L, Cheng Y, Sun PD. 2014. Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis. *PNAS* **111**:5189–5194. DOI: https://doi.org/10.1073/pnas.1322357111, PMID: 24706838
A3 is pro-atherogenic. To better understand the independent mechanism, researchers reconstituted high-density lipoprotein particles formed by lipid interactions with human serum amyloid A. They found that A3 activates novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism. The Journal of Biological Chemistry 285:565–575. DOI: https://doi.org/10.1074/jbc.M110.017840

Serum amyloid A on the structure and antioxidant ability of high-density lipoprotein. Journal of Biological Chemistry 282:13975–13982. DOI: https://doi.org/10.1074/jbc.M701865200

Phospholipase A2-a mediates between proximal and distal effectors of inflammation. Immunochemistry Today 12:143–146. DOI: https://doi.org/10.1016/0167-5699(91)90042-8, PMID: 1878124

Influence of C-terminal truncation of murine Serum amyloid A on fibril structure. Scientific Reports 7:6170. DOI: https://doi.org/10.1038/s41598-017-06419-1, PMID: 28733641

Serum amyloid A - a review. Molecular Medicine 24:46. DOI: https://doi.org/10.1186/s10020-018-0047-0, PMID: 30165816

Effects of serum amyloid A on the structure and antioxidant ability of high-density lipoprotein. Bioscience Reports 36: e00369. DOI: https://doi.org/10.1042/BSR20160075, PMID: 27867516

Serum amyloid A protein enhances the activity of secretory non-pancreatic phospholipase A2. Biochemical Journal 347:461–464. DOI: https://doi.org/10.1016/j.bj.20030916, PMID: 17842869

Inhibition of the activity of pro-inflammatory secretory phospholipase A2 (2) by acute phase proteins. Mediators of Inflammation 5:196–201. DOI: https://doi.org/10.1155/S0962935196000270

Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL. Journal of Lipid Research 39:2150–2160. DOI: https://doi.org/10.1074/jlr.M900588

Effect of lipid environment on amyloid fibril formation of human serum amyloid A. Biochemistry and Physics of Lipids 202:26–30. DOI: https://doi.org/10.1016/j.chemphyslip.2016.11.004, PMID: 27865770

The roles of the secreted phospholipase A2 Gene Family in Immunology. Advances in Immunology 132:91–134. DOI: https://doi.org/10.1016/bs.ai.2016.05.001, PMID: 27769509

Secondary, AA. Amyloidosis. Rheumatic Disease Clinics of North America 44:585–603. DOI: https://doi.org/10.1016/j.rdc.2018.06.004, PMID: 30274625

Secretory non-pancreatic group II phospholipase A2: role in physiologic and inflammatory processes. Journal of Lipid Mediators 8:161–167. PMID: 8268462

Serum amyloid A (SAA) protein is a novel serum amyloid A target gene: activation of smooth muscle cell expression by an interleukin-1 receptor-independent mechanism. The Journal of Biological Chemistry 285:565–575. DOI: https://doi.org/10.1074/jbc.M110.017840, PMID: 19850938

Serum amyloid A is an exchangeable apolipoprotein. Arteriosclerosis, Thrombosis, and Vascular Biology 38:1890–1900. DOI: https://doi.org/10.1161/ATVBAHA.118.130979, PMID: 29976766

Emerging functions of serum amyloid A in inflammation. Journal of leukocyte biology 98:923–929. DOI: https://doi.org/10.1189/jlb.3VR0315-080R, PMID: 26130702

Fibril formation of human serum amyloid A. Advances in Immunology 132:91–134. DOI: https://doi.org/10.1016/bs.ai.2016.05.001, PMID: 27769509